Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Eli Lilly

Moderna

Pfizer

Regeneron Pharmaceuticals

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

Shares of Johnson & Johnson were down 0.1% in premarket trading on Tuesday after the company said in testimony released in advance of a congressional hearing that it plans to deliver about 20 million doses of its COVID-19 vaccine by the end of March. J&J's still-investigational COVID-19 vaccine candidate is currently under review at the Food and Drug Administration, though the federal government has already agreed to purchase 100 million doses of the company's single-dose vaccine in the first half of the year.

J&J plans to deliver 20 million doses of its COVID-19 vaccine in the U.S. in March

Pharmaceuticals giant Johnson & Johnson has set aside $3.9 billion in "litigation expenses," including dealing with a years-long battle over its talc baby powder, of which one bottle was found to contain asbestos. The company set aside the funds "primarily [for] talc related reserves and certain settlements," it said in an SEC filing Monday.

Johnson & Johnson faces 25,000 US lawsuits over its baby powder. Some users say talc in the product caused their cancers.

The clock is ticking until an FDA advisory committee reviews the healthcare giant's vaccine.

What Are Johnson & Johnson's Chances of Success With Its COVID Vaccine?

Drugmaker Johnson & Johnson set aside $3.9 billion in litigation expenses in 2020, which it said was "primarily associated with talc-related reserves and certain settlements".

Johnson & Johnson sets aside almost $4 billion for talc verdict, filing shows

Kroger

Orrstown Financial

Procter & Gamble

AT&T

Vanguard High Dividend Yield ETF

Verizon

Dividend Stock Purchase: Lanny's January 2021 Summary

The U.S. edged closer to half a million deaths from the coronavirus-borne illness COVID-19 on Monday, as experts braced for a Food and Drug Administration advisory committee meeting later this week to review Johnson & Johnson's vaccine candidate.

Coronavirus Update: U.S. edges closer to half a million COVID deaths as experts look to FDA meeting on J&J's one-dose vaccine

Johnson & Johnson's single-dose Covid-19 vaccine has started to roll-out in South Africa. The shot is being administered as part of a research study that is targeting up to half a million healthcare workers and marks the first time the vaccine is being deployed outside of clinical trials.

Johnson & Johnson Covid-19 Vaccine Updates: South African Roll-out, FDA Reviews

Honeywell

Lockheed Martin

NIKE

PepsiCo

Raytheon Technologies

Union Pacific

In this article series, we provide a summary of upcoming ex-dividend dates.

Upcoming Ex-Dividend Dates: February 22-March 8, 2021

A Food and Drug Administration advisory committee is set to meet Thursday to vote on whether the regulator should authorize Johnson & Johnson's experimental single-dose COVID-19 vaccine. Shares of J&J were up 0.5% in premarket trading on Monday.

FDA committee to review J&J's COVID-19 vaccine candidate on Thursday

Amgen

Air Products and Chemicals

Blackrock Inc

Cisco Systems

CVS Health

Con Ed

Eastman Chemical

Genuine Parts

Home Depot

International Flavors & Fragrances

Illinois Tool Works

Leggett & Platt

Main Street Capital

Magellan Midstream Partners

Realty Income Corp

Walmart

Exxon Mobil

Equity markets were generally down for the month of January with the S&P 500 finishing down 1%. The Sand In Shoes portfolio finished slightly better, up 0.15% for the month.

Sand In My Shoes - January Update

Target

Don't stress out over your stocks -- here are three that guarantee sweet dreams and healthy returns.

Successful Investors Share 3 Investments That Won't Keep You Awake at Night

Familiar names and newcomers are rushing to the forefront.

The Johnson & Johnson Vaccine Has Competition in the Race to Treat New Strains

AstraZeneca

The two big drugmakers' vaccine fortunes recently went in opposite directions.

Will AstraZeneca's Pain Be Johnson & Johnson's Gain?

Alibaba

Bank of America

Baidu

Bank of New York Mellon

Tweedy Browne (Trades, Portfolio) recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Tweedy Browne's Top 4th-Quarter Trades

Emergency use listing would clear the way for Johnson & Johnson to distribute its vaccine through the Covax initiative, a W.H.O.-backed effort to get shots to poorer countries.

Johnson & Johnson Applies For Emergency Use Vaccine Approval At W.H.O.

Shares of Johnson & Johnson gained 0.4% in premarket trading on Friday after the company said it had submitted an application for its experimental single-dose COVID-19 vaccine to the World Health Organization for emergency authorization. Obtaining an emergency-use listing from the WHO allows J&J's vaccine candidate to be made available through Covax, a global consortium supplying COVID-19 vaccines to lower-income countries.

J&J submits application for its COVID-19 vaccine to the WHO

NEW BRUNSWICK, N.J., Feb. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine...

Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

Novavax

As Covid-19 becomes endemic, rich governments will turn to Novavax to vaccinate people in developing economies. NVAX stock will benefit.

News for Johnson & Johnson Stock (JNJ)